Get the Stockscreener App
0.391
3.34%
-0.0135
After Hours:
.39
-0.001
-0.26%
Leap Therapeutics Inc stock is traded at $0.391, with a volume of 227.38K.
It is down -3.34% in the last 24 hours and down -23.03% over the past month.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$0.4045
Open:
$0.4
24h Volume:
227.38K
Relative Volume:
0.31
Market Cap:
$14.98M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.2341
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-11.20%
1M Performance:
-23.03%
6M Performance:
-85.73%
1Y Performance:
-82.93%
1-Day Range:
$0.391
$0.4189
1-Week Range:
$0.391
$0.455
52-Week Range:
$0.391
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.391 | 14.98M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline - Investing.com India
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com
Sun Pharma's Strategic Leap: Acquiring Checkpoint Therapeutics - Devdiscourse
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Leap Therapeutics (LPTX) to Release Quarterly Earnings on Monday - Defense World
Gastric Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Earnings To Watch: L.B. Foster (FSTR) Reports Q4 Results Tomorrow - The Globe and Mail
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors - ACCESS Newswire
Nebius Stock Investors Have Reason to Cheer as the Company Expands Rapidly Into AI Infrastructure - The Globe and Mail
Leap Therapeutics stock hits 52-week low at $0.47 amid downturn - Investing.com Canada
Keurig Dr Pepper Earnings: What To Look For From KDP - The Globe and Mail
Amicus Therapeutics’ Bold Leap Toward Billion-Dollar Milestone - Smartphone Magazine
Cathie Wood Keeps Dumping Palantir Stock. Should You? - The Globe and Mail
Got $3,500? Should You Buy Ethereum or XRP (Ripple)? - The Globe and Mail
Biliary Tumor Market Set to Grow Substantially Through 2032, - openPR
Recent Insider Activity Suggests Potential Gains for Vaxart Inc (VXRT) - Knox Daily
Analytical Lens: Exploring Leap Therapeutics Inc (LPTX)’s Financial Story Through Ratios - The Dwinnex
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Get in on Leap Therapeutics Inc’s (LPTX) buy-in window today! - SETE News
Leap Therapeutics Inc (LPTX) stock analysis: A simple moving average approach - US Post News
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment - Yahoo Finance
What is HC Wainwright's Estimate for LPTX FY2029 Earnings? - MarketBeat
Analyzing Leap Therapeutics Inc (NASDAQ: LPTX) Stock’s Performance and Trends for Investment - Marketing Sentinel
Leap Therapeutics (NASDAQ:LPTX) Downgraded by Baird R W to "Hold" - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Cut to "Neutral" at Robert W. Baird - MarketBeat
FY2029 Earnings Estimate for LPTX Issued By HC Wainwright - Defense World
Robert W. Baird Downgrades Leap Therapeutics (NASDAQ:LPTX) to Neutral - Defense World
Leap Therapeutics (NASDAQ:LPTX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Needham & Company LLC Upgrades Open Lending (NASDAQ:LPRO) to Buy - Defense World
Leap Therapeutics Reports Promising Initial Clinical Data, Updates Corporate Presentation - Defense World
Baird R W Downgrades Leap Therapeutics (NASDAQ:LPTX) to Hold - Defense World
Leap reports positive colorectal cancer study results - MSN
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral - MSN
Baird cuts Leap Therapeutics stock rating, slashes target - MSN
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer - Nature.com
Leap Therapeutics stock hits 52-week low at $0.8 - MSN
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback - MSN
Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright -January 29, 2025 at 03:02 pm EST - Marketscreener.com
Leap Therapeutics stock cut to Neutral at Baird (LPTX:NASDAQ) - Seeking Alpha
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Biliary Tract Cancer Market Poised for Significant Growth from - openPR
Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9 - Marketscreener.com
HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy -January 29, 2025 at 07:17 am EST - Marketscreener.com
Leap halts gastric cancer program, changes course - The Pharma Letter
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline - MSN
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipe - Asianet Newsable
Leap Therapeutics stock hits 52-week low at $0.8 By Investing.com - Investing.com Nigeria
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):